CANF Can-Fite BioPharma Ltd: רווח למניה ב-12 החודשים האחרונים

Risks for Can-Fite BioPharma (CANF) are linked to the narrow market for A3AR agonists in oncology. The year-over-year change in EPS (TTM) illustrates this volatility, where the current parameter equals 82.80. Growth potential is driven by molecule patents that guarantee pricing power, although revenue is currently limited to Asian licenses at the late-stage clinical trial phase.

This metric reflects the rolling year net income per share, allowing for an assessment of business capitalization efficiency through historical EPS YoY growth over the last 12 months. A positive trend in this metric confirms the ability of Can-Fite BioPharma (CANF) to monetize unique patents in oncology and hepatology, creating a sustainable barrier against pricing pressure from generics.